TY - JOUR
T1 - Inflammatory breast cancer
T2 - the disease, the biology, the treatment
AU - Robertson, Fredika M.
AU - Bondy, Melissa
AU - Yang, Wei
AU - Yamauchi, Hideko
AU - Wiggins, Shannon
AU - Kamrudin, Samira
AU - Krishnamurthy, Savitri
AU - Le-Petross, Huong
AU - Bidaut, Luc
AU - Player, Audrey N.
AU - Barsky, Sanford H.
AU - Woodward, Wendy A.
AU - Buchholz, Thomas
AU - Lucci, Anthony
AU - Ueno, Naoto
AU - Cristofanilli, Massimo
PY - 2010
Y1 - 2010
N2 - Inflammatory breast cancer (IBC) is a rare and aggressive form of invasive breast cancer accounting for 2.5% of all breast cancer cases. It is characterized by rapid progression, local and distant metastases, younger age of onset, and lower overall survival compared with other breast cancers. Historically, IBC is a lethal disease with less than a 5% survival rate beyond 5 years when treated with surgery or radiation therapy. Because of its rarity, IBC is often misdiagnosed as mastitis or generalized dermatitis. This review examines IBC's unique clinical presentation, pathology, epidemiology, imaging, and biology and details current multidisciplinary management of the disease, which comprises systemic therapy, surgery, and radiation therapy. CA Cancer J Clin 2010;60:351-375. (C) 2010 American Cancer Society, Inc.
AB - Inflammatory breast cancer (IBC) is a rare and aggressive form of invasive breast cancer accounting for 2.5% of all breast cancer cases. It is characterized by rapid progression, local and distant metastases, younger age of onset, and lower overall survival compared with other breast cancers. Historically, IBC is a lethal disease with less than a 5% survival rate beyond 5 years when treated with surgery or radiation therapy. Because of its rarity, IBC is often misdiagnosed as mastitis or generalized dermatitis. This review examines IBC's unique clinical presentation, pathology, epidemiology, imaging, and biology and details current multidisciplinary management of the disease, which comprises systemic therapy, surgery, and radiation therapy. CA Cancer J Clin 2010;60:351-375. (C) 2010 American Cancer Society, Inc.
KW - Positron emission tomography
KW - Growth factor receptor
KW - Epitheleal mesenchymal transition
KW - Lymph node metastases
KW - Human melanoma cells
KW - Body mass index
KW - Neoadjuvant chemotherapy
KW - Vasculogenic mimicry
KW - Gene expression
KW - RHOC GTPASE
U2 - 10.3322/caac.20082
DO - 10.3322/caac.20082
M3 - Article
C2 - 20959401
SN - 0007-9235
VL - 60
SP - 351
EP - 375
JO - CA: a Cancer Journal for Clinicians
JF - CA: a Cancer Journal for Clinicians
IS - 6
ER -
